Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended vutrisiran study in transthyretin amyloidosis with cardiomyopathy
NL-OMON59781Phase 3Active, not recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Apr 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of vutrisiran in transthyretin amyloidosis (ATTR) (2 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Frequency of adverse events. Started Apr 2025; status: active, not recruiting.
02
Drugs
vutrisiran
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NL-OMON59781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59781.